• José M Baena-Cañada, Salvador Gámez-Casado, Lourdes Rodríguez-Pérez, Cristina Bandera-López, Andrés Mesas-Ruiz, Alicia Campini-Bermejo, Marta Bernal-Gómez, Manuel Zalabardo-Aguilar, Julio Calvete-Candenas, Gala Martínez-Bernal, Alicia Quílez-Cutillas, Lidia Atienza-Cuevas, Marcial García-Rojo, Encarnación Benítez-Rodríguez, Bella Pajares-Hachero, and María José Bermejo-Pérez.
• Servicio de Oncología Médica. Hospital Universitario Puerta del Mar, Cádiz, España; Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Cádiz, España. Electronic address: josem.baena.sspa@juntadeandalucia.es.
• Med Clin (Barc). 2022 Oct 28; 159 (8): 351358351-358.

Background And ObjectiveTo identify subgroups with good progress over an extended period, we used diagnostic screening, tumour palpability, tumour phenotype, and node involvement.Patients And MethodsWe identified patients with good progress by means of a descriptive, observational and retrospective study.ResultsOf 746 patients diagnosed with node-negative breast cancer between 2001 and 2015: 110 (14.75%) had non-palpable screening-diagnosed tumours; 88 (80%) were endocrine-sensitive, 10 (9.10%) were triple-negative and 11 (10%) were HER2. Only 3 patients developed metastases, and there were 4 deaths: 2 from breast cancer and 2 from other causes. The distant recurrence-free interval (DRFI) was 95.60%: 100% in 34 endocrine-sensitive histological grade 1 (equivalent to luminal A) tumours, and 94.40% (95% CI 86.76-102.04) in 54 grade 2-3 (luminal B) tumours. In triple-negative and HER2 cases, it was 100%. In tumours <1 cm it was 100%, and >1 cm it was 95.50% (95% CI 79.42-100.98).ConclusionsPatients with non-palpable tumours detected by mammogram screening have ultralow risk. The good progress in the luminal A, triple-negative, HER2, and less than 1 cm subgroups may explain the efficacy of the treatment but it also makes them candidates to de-escalation of their treatment.Copyright © 2022 Elsevier España, S.L.U. All rights reserved.

12 keywords...

hide…